Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Plaque Psoriasis Treatments: BMS-986165 Promising & Adalimumab Biosimilar Demonstrates Equivalence

  |  

References

  1. Bristol-Myers Squibb. News release: Bristol-Myers Squibb’s novel, oral, selective TYK2 inhibitor delivered significant skin clearance in patients with moderate to severe plaque psoriasis in phase 2 trial. 2018 Sep 12.
  2. Boehringer Ingelheim. News release: Biosimilar Cyltezo demonstrates clinical equivalence to Humira in patients with moderate to severe plaque psoriasis. 2018 Sep 12.
  3. Boehringer Ingelheim. Efficacy, safety and immunogenicity of BI695501 vs. Humira in patients with moderate to severe chronic plaque psoriasis. ClinicalTrials.gov. 2018 May 23.

Related Articles
    MicroOne / shutterstock.com

    Rheumatology Drugs at a Glance, Part 2: Psoriasis

    Over the past few years, bio­similars and other new drugs have been introduced to treat rheumatic illnesses. Some of the conditions we treat have numerous drug option; others have few or only off-label options. This series, “Rheumatology Drugs at a Glance,” provides streamlined information on the administration of biologic, biosimilar and other medications used to…